These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 7975207)
1. Activity and cleavage site specificity of an anti-HIV-1 hairpin ribozyme in human T cells. Yamada O; Kraus G; Leavitt MC; Yu M; Wong-Staal F Virology; 1994 Nov; 205(1):121-6. PubMed ID: 7975207 [TBL] [Abstract][Full Text] [Related]
2. Conservation of a hairpin ribozyme sequence in HIV-1 is required for efficient viral replication. Yamada O; Kraus G; Sargueil B; Yu Q; Burke JM; Wong-Staal F Virology; 1996 Jun; 220(2):361-6. PubMed ID: 8661387 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of HIV-1 replication by retroviral vectors expressing monomeric and multimeric hammerhead ribozymes. Ramezani A; Ding SF; Joshi S Gene Ther; 1997 Aug; 4(8):861-7. PubMed ID: 9338016 [TBL] [Abstract][Full Text] [Related]
4. Intracellular immunization of human T cells with a hairpin ribozyme against human immunodeficiency virus type 1. Yamada O; Yu M; Yee JK; Kraus G; Looney D; Wong-Staal F Gene Ther; 1994 Jan; 1(1):38-45. PubMed ID: 7584058 [TBL] [Abstract][Full Text] [Related]
5. A novel ribozyme target site located in the HIV-1 nef open reading frame. Larsson S; Hotchkiss G; Su J; Kebede T; Andäng M; Nyholm T; Johansson B; Sönnerborg A; Vahlne A; Britton S; Ahrlund-Richter L Virology; 1996 May; 219(1):161-9. PubMed ID: 8623525 [TBL] [Abstract][Full Text] [Related]
6. Retrovirally expressed anti-HIV ribozymes confer a selective survival advantage on CD4+ T cells in vitro. Klebba C; Ottmann OG; Scherr M; Pape M; Engels JW; Grez M; Hoelzer D; Klein SA Gene Ther; 2000 Mar; 7(5):408-16. PubMed ID: 10694823 [TBL] [Abstract][Full Text] [Related]
7. Ex vivo transduction and expansion of CD4+ lymphocytes from HIV + donors: prelude to a ribozyme gene therapy trial. Leavitt MC; Yu M; Wong-Staal F; Looney DJ Gene Ther; 1996 Jul; 3(7):599-606. PubMed ID: 8818647 [TBL] [Abstract][Full Text] [Related]
8. Receptor ligand-facilitated cationic liposome delivery of anti-HIV-1 Rev-binding aptamer and ribozyme DNAs. Konopka K; Düzgüneş N; Rossi J; Lee NS J Drug Target; 1998; 5(4):247-59. PubMed ID: 9713975 [TBL] [Abstract][Full Text] [Related]
9. Comparative analysis of five highly conserved target sites within the HIV-1 RNA for their susceptibility to hammerhead ribozyme-mediated cleavage in vitro and in vivo. Ramezani A; Joshi S Antisense Nucleic Acid Drug Dev; 1996; 6(3):229-35. PubMed ID: 8915508 [TBL] [Abstract][Full Text] [Related]
10. Engineered RNase P ribozymes inhibit gene expression and growth of cytomegalovirus by increasing rate of cleavage and substrate binding. Trang P; Hsu A; Zhou T; Lee J; Kilani AF; Nepomuceno E; Liu F J Mol Biol; 2002 Jan; 315(4):573-86. PubMed ID: 11812131 [TBL] [Abstract][Full Text] [Related]
11. Design of the hairpin ribozyme for targeting specific RNA sequences. Hampel A; DeYoung MB; Galasinski S; Siwkowski A Methods Mol Biol; 1997; 74():171-7. PubMed ID: 9204432 [TBL] [Abstract][Full Text] [Related]
12. Cleavage of the highly conserved hairpin-loop region of HIV-1 by synthetic ribozymes. Shimayama T; Nishikawa S; Taira K Nucleic Acids Symp Ser; 1993; (29):177-8. PubMed ID: 8247758 [TBL] [Abstract][Full Text] [Related]
13. Hairpin antisense oligonucleotides containing 2'-methoxynucleosides with base-pairing in the stem region at the 3'-end: penetration, localization, and Anti-HIV activity. Kuwasaki T; Hosono K; Takai K; Ushijima K; Nakashima H; Saito T; Yamamoto N; Takaku H Biochem Biophys Res Commun; 1996 Nov; 228(2):623-31. PubMed ID: 8920960 [TBL] [Abstract][Full Text] [Related]
15. Long-term RNase P-mediated inhibition of HIV-1 replication and pathogenesis. Hnatyszyn H; Spruill G; Young A; Seivright R; Kraus G Gene Ther; 2001 Dec; 8(24):1863-71. PubMed ID: 11821940 [TBL] [Abstract][Full Text] [Related]
16. Multiple folded conformations of a hammerhead ribozyme domain under cleavage conditions. Woisard A; Fourrey JL; Favre A J Mol Biol; 1994 Jun; 239(3):366-70. PubMed ID: 8201618 [TBL] [Abstract][Full Text] [Related]
17. Activities of HIV-RNA targeted ribozymes transcribed from a 'shot-gun' type ribozyme-trimming plasmid. Ohkawa J; Yuyama N; Taira K Nucleic Acids Symp Ser; 1992; (27):15-6. PubMed ID: 1289797 [TBL] [Abstract][Full Text] [Related]
18. Nucleotide sequences within the U5 region of the viral RNA genome are the major determinants for an human immunodeficiency virus type 1 to maintain a primer binding site complementary to tRNA(His). Zhang Z; Kang SM; LeBlanc A; Hajduk SL; Morrow CD Virology; 1996 Dec; 226(2):306-17. PubMed ID: 8955050 [TBL] [Abstract][Full Text] [Related]
19. Anti-HIV genetic treatment of antigen-specific human CD4 lymphocytes for adoptive immunotherapy of opportunistic infections in AIDS. Manca F; Fenoglio D; Franchin E; Saverino D; Li Pira G; Buffa F; Bignardi D; Del Pup L; Palù G Gene Ther; 1997 Nov; 4(11):1216-24. PubMed ID: 9425445 [TBL] [Abstract][Full Text] [Related]
20. Hairpin ribozyme specificity in vivo: a case of promiscuous cleavage. Denman RB Biochem Biophys Res Commun; 1999 Apr; 257(2):356-60. PubMed ID: 10198217 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]